WO2004101621A1 - Immunoglobuline (ig) y specifique contre le syndrome respiratoire aigu severe (sras), technique de preparation de celle-ci et combinaison de preparations contenant celle-ci - Google Patents
Immunoglobuline (ig) y specifique contre le syndrome respiratoire aigu severe (sras), technique de preparation de celle-ci et combinaison de preparations contenant celle-ci Download PDFInfo
- Publication number
- WO2004101621A1 WO2004101621A1 PCT/CN2003/000587 CN0300587W WO2004101621A1 WO 2004101621 A1 WO2004101621 A1 WO 2004101621A1 CN 0300587 W CN0300587 W CN 0300587W WO 2004101621 A1 WO2004101621 A1 WO 2004101621A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sars
- igy
- coronavirus
- atypical pneumonia
- add
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 47
- 108060003951 Immunoglobulin Proteins 0.000 title abstract description 4
- 230000001154 acute effect Effects 0.000 title abstract description 4
- 102000018358 immunoglobulin Human genes 0.000 title abstract description 4
- 208000011580 syndromic disease Diseases 0.000 title 1
- 241000700605 Viruses Species 0.000 claims abstract description 120
- 239000000427 antigen Substances 0.000 claims abstract description 77
- 102000036639 antigens Human genes 0.000 claims abstract description 77
- 108091007433 antigens Proteins 0.000 claims abstract description 77
- 235000013601 eggs Nutrition 0.000 claims abstract description 47
- 238000002360 preparation method Methods 0.000 claims abstract description 41
- 239000000287 crude extract Substances 0.000 claims abstract description 19
- 201000010099 disease Diseases 0.000 claims abstract description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 14
- 239000000284 extract Substances 0.000 claims abstract description 14
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- 206010003757 Atypical pneumonia Diseases 0.000 claims description 175
- 241000711573 Coronaviridae Species 0.000 claims description 125
- 230000001717 pathogenic effect Effects 0.000 claims description 71
- 239000000243 solution Substances 0.000 claims description 71
- 238000003756 stirring Methods 0.000 claims description 47
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 39
- 210000004027 cell Anatomy 0.000 claims description 35
- 238000002347 injection Methods 0.000 claims description 30
- 239000007924 injection Substances 0.000 claims description 30
- 241000272517 Anseriformes Species 0.000 claims description 28
- 239000012153 distilled water Substances 0.000 claims description 28
- 210000002969 egg yolk Anatomy 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 26
- 239000006228 supernatant Substances 0.000 claims description 26
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 24
- 230000003053 immunization Effects 0.000 claims description 20
- 238000002649 immunization Methods 0.000 claims description 20
- 239000007921 spray Substances 0.000 claims description 20
- 239000000843 powder Substances 0.000 claims description 19
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 18
- 238000002965 ELISA Methods 0.000 claims description 18
- 241000315672 SARS coronavirus Species 0.000 claims description 18
- 238000004113 cell culture Methods 0.000 claims description 18
- 238000000108 ultra-filtration Methods 0.000 claims description 18
- 235000013345 egg yolk Nutrition 0.000 claims description 17
- 241000272525 Anas platyrhynchos Species 0.000 claims description 16
- 241000272814 Anser sp. Species 0.000 claims description 16
- 108010011485 Aspartame Proteins 0.000 claims description 16
- 239000000605 aspartame Substances 0.000 claims description 16
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 16
- 229960003438 aspartame Drugs 0.000 claims description 16
- 235000010357 aspartame Nutrition 0.000 claims description 16
- 239000000796 flavoring agent Substances 0.000 claims description 16
- 235000019634 flavors Nutrition 0.000 claims description 16
- 241000272534 Struthio camelus Species 0.000 claims description 14
- 239000001963 growth medium Substances 0.000 claims description 14
- 239000000047 product Substances 0.000 claims description 13
- 239000002002 slurry Substances 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 12
- 238000003306 harvesting Methods 0.000 claims description 12
- 230000017448 oviposition Effects 0.000 claims description 12
- 241000271567 Struthioniformes Species 0.000 claims description 11
- 239000002131 composite material Substances 0.000 claims description 11
- 102000002322 Egg Proteins Human genes 0.000 claims description 10
- 108010000912 Egg Proteins Proteins 0.000 claims description 10
- 239000002671 adjuvant Substances 0.000 claims description 10
- 239000006199 nebulizer Substances 0.000 claims description 10
- 206010061218 Inflammation Diseases 0.000 claims description 9
- 102000004895 Lipoproteins Human genes 0.000 claims description 9
- 108090001030 Lipoproteins Proteins 0.000 claims description 9
- 229930182555 Penicillin Natural products 0.000 claims description 9
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 9
- 238000010790 dilution Methods 0.000 claims description 9
- 239000012895 dilution Substances 0.000 claims description 9
- 235000014103 egg white Nutrition 0.000 claims description 9
- 210000000969 egg white Anatomy 0.000 claims description 9
- 230000028993 immune response Effects 0.000 claims description 9
- 230000004054 inflammatory process Effects 0.000 claims description 9
- 229940049954 penicillin Drugs 0.000 claims description 9
- 229920006395 saturated elastomer Polymers 0.000 claims description 9
- 239000002356 single layer Substances 0.000 claims description 9
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 8
- 241000271566 Aves Species 0.000 claims description 8
- 240000005809 Prunus persica Species 0.000 claims description 8
- 235000006040 Prunus persica var persica Nutrition 0.000 claims description 8
- 239000012228 culture supernatant Substances 0.000 claims description 8
- 238000009775 high-speed stirring Methods 0.000 claims description 8
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims description 8
- 239000012528 membrane Substances 0.000 claims description 8
- 239000007968 orange flavor Substances 0.000 claims description 8
- 239000000661 sodium alginate Substances 0.000 claims description 8
- 235000010413 sodium alginate Nutrition 0.000 claims description 8
- 229940005550 sodium alginate Drugs 0.000 claims description 8
- 230000001580 bacterial effect Effects 0.000 claims description 7
- 239000003085 diluting agent Substances 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 6
- 210000000987 immune system Anatomy 0.000 claims description 6
- 230000036039 immunity Effects 0.000 claims description 6
- 244000144977 poultry Species 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 5
- 238000007796 conventional method Methods 0.000 claims description 5
- 230000003902 lesion Effects 0.000 claims description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- 241000286209 Phasianidae Species 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 238000005342 ion exchange Methods 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 4
- 238000010298 pulverizing process Methods 0.000 claims description 4
- 238000010254 subcutaneous injection Methods 0.000 claims description 4
- 239000007929 subcutaneous injection Substances 0.000 claims description 4
- 210000003462 vein Anatomy 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 claims description 3
- 230000000675 anti-caries Effects 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 239000002504 physiological saline solution Substances 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- 210000002345 respiratory system Anatomy 0.000 claims description 3
- 238000012387 aerosolization Methods 0.000 claims description 2
- 238000000265 homogenisation Methods 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 239000003380 propellant Substances 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 238000004440 column chromatography Methods 0.000 claims 6
- 229920005654 Sephadex Polymers 0.000 claims 5
- 239000012507 Sephadex™ Substances 0.000 claims 5
- 241000193998 Streptococcus pneumoniae Species 0.000 claims 3
- 239000012141 concentrate Substances 0.000 claims 3
- 238000011534 incubation Methods 0.000 claims 3
- 239000000463 material Substances 0.000 claims 3
- 230000002708 enhancing effect Effects 0.000 claims 2
- 238000011049 filling Methods 0.000 claims 2
- 230000001954 sterilising effect Effects 0.000 claims 2
- 208000003322 Coinfection Diseases 0.000 claims 1
- 230000001775 anti-pathogenic effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000005227 gel permeation chromatography Methods 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- 230000007918 pathogenicity Effects 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 238000004659 sterilization and disinfection Methods 0.000 claims 1
- 238000002955 isolation Methods 0.000 abstract description 2
- 230000000241 respiratory effect Effects 0.000 abstract 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 110
- 230000000694 effects Effects 0.000 description 17
- 244000052769 pathogen Species 0.000 description 15
- 230000002401 inhibitory effect Effects 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000001514 detection method Methods 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 206010035664 Pneumonia Diseases 0.000 description 6
- 206010037660 Pyrexia Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 230000005934 immune activation Effects 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 4
- 241000287828 Gallus gallus Species 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 239000003862 glucocorticoid Substances 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 229940037128 systemic glucocorticoids Drugs 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 3
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 3
- 239000006189 buccal tablet Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 229960000329 ribavirin Drugs 0.000 description 3
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000002636 symptomatic treatment Methods 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229940046011 buccal tablet Drugs 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000032139 Halitosis Diseases 0.000 description 1
- 206010035742 Pneumonitis Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 101000980463 Treponema pallidum (strain Nichols) Chaperonin GroEL Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000000423 heterosexual effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000007967 peppermint flavor Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 238000002333 serotherapy Methods 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/38011—Tombusviridae
- C12N2770/38034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Definitions
- the invention relates to an anti-atypical pneumonia (SARS) specific IgY and a preparation method thereof, in particular to a multiple IgY composite preparation method and a combined preparation for preventing and treating atypical pneumonia.
- SARS anti-atypical pneumonia
- Atypical pneumonia also known as "Severe Acute Respiratory Syndrome (SARS)
- SARS severe Acute Respiratory Syndrome
- WHO World Health Organization
- a variant of the virus is the pathogen that causes atypical pneumonia. This disease is acute, with fever as the first symptom, and has cough (mostly dry), less sputum, and severe cases of rapid breathing, shortness of breath, or obvious breathing Distressed.
- SARS atypical pneumonia
- antiviral drugs such as Ribavirin (triazole), etc.
- glucocorticoids and antibiotics or Chinese herbal medicine At present, there are no chemicals that have a true cure for the virus worldwide, and severe side effects are widespread. Health Canada based on the clinical experience of experts from the Canadian and U.S. Centers for Disease Control and Prevention, and Ribavirin's ineffective testing of the disease-causing coronavirus, plus many serious drug response reports, which were published in 2003. On May 1st, Ribavirin was discontinued.
- the use of glucocorticoids can damage the body's immune system. Large doses of glucocorticoids are often the main reason that patients eventually die without responding to the drug. Chinese herbal medicine only has a conditioning effect on atypical pneumonia (SARS), and it is difficult to have a precise and effective treatment effect.
- IgY immunoglobulin of Yoik
- IgG immunoglobulin that can specifically bind to the corresponding antigen, thereby inhibiting or changing the state or activity of the antigen (for certain bacteria or viruses), and promoting leaf separation through conditioning Nuclear cells or macrophages engulf bacteria or viruses; it can bind to viruses, change the conformation of the virus surface, prevent the virus from adsorbing to susceptible cells, and at the same time, the formed virus-IgY immune complex will be engulfed by macrophages.
- the purpose of the present invention is to provide a specific IgY that directly inhibits the main pathogenic virus of atypical pneumonia (SARS) and a method for preparing the same; the object of the present invention is also to provide a method that can directly inhibit the main cause of atypical pneumonia (SARS).
- the virus-specific IgY is a new combination of natural and safe, and effective, preventive and treatment of atypical pneumonia (SARS).
- SARS atypical pneumonia
- SARS atypical pneumonia coronavirus
- SARS coronavirus coronavirus as a representative atypical pneumonia (SARS) pathogen.
- SARS coronavirus coronavirus
- the representative pathogenic combination of atypical pneumonia (SARS) can be adjusted and changed in time.
- the present invention takes the Hong Kong group as an example.
- the Vero E6 cells were seeded in 10% FCS DMEM culture medium, the final cell concentration of IX 10 5 / ml.
- 15 ml of the above-mentioned culture solution was placed in a 100 ml culture flask, and the culture flask was placed at 37 ° C in a 5% CCh saturation incubator to culture into monolayer cells.
- the culture medium was then discarded, and the 4 different SARS coronavirus strains collected in Hong Kong were diluted to 100 TCID 50 with 2% FCS and 1% penicillin DMEM culture medium.
- the atypical pneumonia (SARS) pathogenic virus antigen prepared by the above method will be used to immunize laying hens separately; then strengthen every two weeks One injection and three immunizations are counted; 20 days after the first immunization, the immune eggs produced by the hens after immunization are detected, and corresponding detected antigens are coded and labeled.
- SARS atypical pneumonia
- the above immunization method and injection frequency can be appropriately adjusted and changed according to the actual situation; the same immunization technology can also be applied and the above antigens can be used to lay laying ducks, laying geese, laying turkeys, or laying ostriches, etc. Laying birds are immunized to obtain corresponding immune eggs.
- SARS virus specific IgY crude extracts First, classify and label the immune eggs according to the different immunized birds and the antigens used for immunization, and wash the immune eggs with flowing water. , And then scrub and disinfect with alcohol; use an eggbeater to break the detected immune eggs, filter the egg white with an yolk sieve, leave the egg yolks, stir the hooks, and measure the volume of the resulting egg yolks. Add distilled water twice, dilute and mix well, adjust the pH to 5.5-6.0 with NaOH solution;
- the diluted diluent with the adjusted pH value is further fully stirred and homogenized, and then it is cooled to 2-6 ° C and left to stand for 12 hours to 24 hours.
- the diluent is added to a high-speed centrifuge and centrifuged for 20 minutes.
- the supernatant was added to an ultrafilter for ultrafiltration and concentrated 10-20 times.
- Sodium alginate was added to the concentrated slurry at a ratio of 0.1 to 0.3%, and stirred thoroughly; and then added to a high-speed centrifuge to centrifuge.
- the SDS-PAGE electrophoresis assay was used to detect the crude IgY extracts specific to the atypical pneumonia (SARS) pathogenic virus prepared according to the above process, and the pure IgY content was measured to be above 50%.
- SARS atypical pneumonia
- the anti-atypical pneumonia (SARS) pathogenic virus-specific IgY prepared by the above method is mixed with distilled water or physiological saline to prepare a solvent with a concentration of 0.01% or more, to prepare a new type of atomizer, and add it to various atomizers. After aerosolization, it can be used for patients with atypical pneumonia to inhale the respiratory tract and lungs, and can effectively inhibit the pathogenic virus that causes atypical pneumonia, thereby playing an effective therapeutic role.
- SARS anti-atypical pneumonia
- various clinically acceptable dosage forms can be made, such as nebulizer, nasal spray, nasal drops, and throat spray.
- Oral sprays, buccal tablets and other dosage forms are used to prevent and treat atypical pneumonia (SARS).
- SARS atypical pneumonia
- this anti-atypical pneumonia (SARS) pathogenic virus-specific IgY can also be added to our company's published patent technology (Patent Application No. 00101270.3, patent, patent No. 00101270.3, 2 : 1 or 3: 1 or other appropriate ratio).
- Publication No. 1307061 prepared anti-caries IgY, a new type of multi-functional specific composite IgY. Mixing this multi-effect specific compound IgY with excipients to make a spray or buccal tablet, as long as the spray is often used to spray the mouth and throat, or the new buccal tablet is often taken, it can be very convenient, Easily both prevent atypical pneumonia (SARS), prevent tooth decay, and eliminate oral inflammation and halitosis.
- SARS prevent atypical pneumonia
- the present invention also designs the practically applied dosage form and application method to directly apply to the lungs with the most concentrated pathogen And breathing channels, so the effect is direct, the target is accurate, the root cause is broken, and the effect is significant.
- the present invention fundamentally changes the current situation of treating atypical pneumonia (SARS), which generally requires a large number of internal medicines and hormones with indefinite curative effects, avoids damaging the patient's immune function, and overcomes the need for conventional methods of administration. A lot of chemicals enter the body ,
- the anti-atypical pneumonia (SARS) -specific IgY prepared by the present invention is also a unique pure natural biological agent, which is very safe to use without any toxic and side effects. Because it only directly targets the pathogenic pathogen of atypical pneumonia, The beneficial bacteria have a good protective effect; at the same time, it will not induce the production of drug-resistant strains at all, and it will also kill the beneficial bacteria together with the pathogens and cause "imbalance of the flora" like the general conventional drugs; The specific IgY of the present invention against atypical pneumonia (SARS) pathogens can build a normal flora ecology in pneumonia and the respiratory tract that is not easily infected by viruses and pathogenic bacteria, forming a natural protective barrier for the human body to achieve both treatment and prevention Dual purpose.
- SARS atypical pneumonia
- the specific IgY prepared by the present invention is a polyclonal antibody, which can inhibit several different pathogens, which is particularly significant for the pathogen-variant coronavirus of atypical pneumonia (SARS). Because this new type of coronavirus is particularly susceptible to mutation, only four have been found in Hong Kong. If a vaccine is to be developed, multiple vaccines are needed to achieve effective control. This greatly increases the prevention of this. Difficulty of a malignant infectious disease.
- SARS pathogen-variant coronavirus of atypical pneumonia
- the specific Ig of the present invention not only has an effect on mutant coronavirus of arbitrary type atypical pneumonia (SARS) directly immunized as an antigen, but also because highly conserved mammalian proteins are germlineally distant to birds It has strong immunogenicity; therefore, as long as a certain antigen is used to immunize birds with the patented immune activation patented technology (patent application number 02121244.9) invented by the company, the specific IgY produced will have a "common antigen" with the antigen. "Determinant" pathogens have strong inhibitory activity. That is, even if the coronavirus is mutated to some extent, its important part will not change in fact; the specific IgY of the present invention will still have an effect on its important part.
- SARS arbitrary type atypical pneumonia
- the Hong Kong type 1 coronavirus prepares the antigen according to the method of Article 2 of the above technical content, and hens are immunized with this antigen, and the method of Article 6 of the present invention is used to prepare the anti-Hong Kong type 1 coronavirus-specific IgY. Then, using Hong Kong type 1 coronavirus as the detection antigen, the anti-atypical pneumonia (SARS) -specific IgY antibody binding titer was measured by "ELISA method" (enzyme-linked immunosorbent assay). The results are shown in the following table
- the method of the present invention is used to prepare pathogenic virus antigens, and the immune activation method of the present invention is used to immunize eggs and poultry and prepare corresponding IgY.
- the prepared anti-Hong Kong type 1 coronavirus-specific IgY has The ideal broad spectrum not only has a strong inhibitory effect on the direct immunization of Hong Kong type 1 coronavirus antigen as shown in Experimental Example 1 above, the measured antibody binding titer is quite high (up to 1: 1024); The three other atypical pneumonia (SARS) coronaviruses that are mutated and not directly immunized also have a certain inhibitory effect, and the detected antibody binding titer is still ideal.
- SARS atypical pneumonia
- SARS serum-binding titers of specific IgY to these 5 different antigens.
- the test results are as follows
- SARS Anti-atypical pneumonia
- the method of the present invention uses a variety of pathogenic viruses to prepare a special complex antigen containing a variety of viral components, and then uses this special complex antigen to apply the immune activation method of the present invention to immunize egg-laying poultry.
- the prepared anti-atypical pneumonia (SARS) -specific IgY is particularly good in broad-spectrum.
- SARS atypical pneumonia
- SARS atypical pneumonia coronaviruses that are directly immunized as antigens
- SARS atypical pneumonia
- Atypical pneumonia (SARS) pathogenic virus antigens were prepared according to the method of the technical content (2) of the present invention, and then this antigen was used to immunize laying hens, laying hens, laying geese, laying hens, Egg turkey and laying ostrich. Then, the method of the present invention is used to prepare: (1) anti-atypical pneumonia (SARS) specific chicken IgY, (2) anti-atypical pneumonia (SARS) specific duck IgY, (3) anti-atypical pneumonia (SARS) Specific goose IgY, (4) anti-atypical pneumonia (SARS) specific turkey IgY, (5) anti-atypical pneumonia (SARS) specific ostrich IgY.
- SARS anti-atypical pneumonia
- Hong Kong type 4 coronavirus 1 256 From the above test results, it can be seen that the method of the present invention is used to make antigens, and the immune activation method is used to immunize hens, female ducks, female geese, laying turkeys or laying ostriches.
- the method of the invention is to prepare anti-atypical pneumonia (SARS) specific chicken IgY, anti-atypical pneumonia (SARS) specific duck IgY, anti-atypical pneumonia (SARS) specific goose IgY, and anti-atypical pneumonia (SARS) specific Turkey IgY, anti-atypical pneumonia (SARS) specific ostrich IgY five different IgY, although the immunized birds are different, the specific IgY prepared is very effective against several pathogenic viruses that cause atypical pneumonia Good suppression effect. Since duck IgY does not have an Fc segment, if duck IgY is made into a dosage form for injection and injected into the human body, the human body is unlikely to produce a rejection reaction, which is the greatest advantage of duck IgY.
- SARS anti-atypical pneumonia
- SARS moderate to severe atypical pneumonia
- the "anti-atypical pneumonia (SARS) specific composite IgY combination nebulizer" of the present invention is atomized using a compressed atomizing air pump. After the patient inhaled. Inhale every two hours for 5-10 minutes.
- SARS anti-atypical pneumonia
- the "anti-atypical pneumonia (SARS) specific IgY” of the present invention can directly and effectively target the pathogenic virus that causes atypical pneumonia, and solve the problem from the root cause of the disease; on the one hand, neutralize these pathogens and change these The activity of pathogens and promote the body's immune system to eliminate these pathogens.
- the specific IgY of the present invention has a strong broad-spectrum inhibitory ability, and even if certain mutations occur in the pathogenic virus, a certain inhibitory effect will still be produced.
- Antigens were made with Pneumococcus pneumoniae, and 1,000 female ducks were immunized with 1 ml of antigen each time. After the first injection, they were boosted once every two weeks for a total of three times. Seven months after the first injection, The eggs produced by these ducks were labeled and the IgY was extracted according to conventional methods. The titer of the prepared IgY was detected by ELISA (enzyme-linked immunosorbent assay). The immune system with an IgY titer of 256 was selected. 200 ducks with particularly strong response ability, and then use the eggs produced by this batch of ducks to hatch excellent duck breeds, which will grow up to 2-3 months as the preferred special female duck with high immune response ability, and select among them 40
- the present invention takes the Hong Kong group as an example. Vero E6 cells were seeded in 10% FCS DMEM culture medium with a final cell concentration of 1 X 10 5 / mlo. 15 ml of the above culture solution was placed in a 100 ml culture flask, and the culture flask was placed at 37 ° C, saturated with 5% C0 2 Monolayer cells are cultured in an incubator. Then discard the culture solution, dilute the 4 different SARS coronavirus strains collected in Hong Kong with 2% FCS and 1% penicillin DMEM culture solution to 100 TCID 50 / mL. Take 10 ml of this dilution and add to the cell culture.
- the cell culture flask was placed in a 37 ° C, 5% CO 2 saturated humidity incubator for 24 hours, and the virus was harvested when the cell lesion reached ++.
- the culture bottle was thawed three times, and the culture supernatant was collected, put into a high-speed centrifuge, centrifuged at 15000 rpm, and the supernatant was collected.
- Formaldehyde was added to a final concentration of 0.1%, and the four cultured SARS viruses were inactivated at 37 ° C for 24 hours.
- Cultured inactivated virus Store at 4 ° C or -20 ° C.
- the pulper is pulverized and homogenized at a high speed at a speed of 10,000 to 30,000 rpm to form an oil-in-water solution by high-speed stirring, that is, a special complex antigen containing a plurality of different types of viruses caused by atypical pneumonia (SARS) pathogenic viruses is made.
- SARS atypical pneumonia
- SARS coronavirus complex antigen Using the prepared (SARS) coronavirus complex antigen, a combination of subcutaneous injection and wing vein injection was used to intensify the immune system to select special female ducks, and the injection volume of each female duck reached 1-2nd antigen. Intensify the injection once every two weeks, and immunize a total of three times within one month; 20 days after the first immunization, 1,000 immune eggs produced by female ducks were seized;
- SARS anti-atypical pneumonia
- SARS anti-atypical pneumonia
- SARS Anti-Atypical Pneumonia
- SARS anti-atypical pneumonia
- IgY combination solution 200 liters of anti-atypical pneumonia (SARS) pathogenic virus IgY combination solution was formulated according to the following formula;
- SARS Anti-Atypical Pneumonia
- SARS anti-atypical pneumonia
- SARS anti-atypical pneumonia
- SARS anti-atypical pneumonia
- SARS anti-atypical pneumonia
- SARS anti-atypical pneumonia
- SARS anti-caries IgY dry powder
- small mixer to make 300 parts by weight of anti-atypical pneumonia (SARS) and oral inflammation compound IgY dry powder ;
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003255080A AU2003255080A1 (en) | 2003-05-13 | 2003-07-22 | A SPECIFIC IMMUNOGLOBULIN (Ig) Y AGAINST SEVERVE ACUTE RTESPIRATORY SYNDROME (SARS) AND A PREPARING METHOD THEREOF AND COMBINATION PREPARATIOS CONTAINING IT |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN03136101.3 | 2003-05-13 | ||
CNB031361013A CN1318449C (zh) | 2003-05-13 | 2003-05-13 | 抗非典型肺炎(SARS)特异性IgY在制备预防和治疗非典型肺炎的制剂中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004101621A1 true WO2004101621A1 (fr) | 2004-11-25 |
Family
ID=28684496
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2003/000587 WO2004101621A1 (fr) | 2003-05-13 | 2003-07-22 | Immunoglobuline (ig) y specifique contre le syndrome respiratoire aigu severe (sras), technique de preparation de celle-ci et combinaison de preparations contenant celle-ci |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN1318449C (zh) |
AU (1) | AU2003255080A1 (zh) |
WO (1) | WO2004101621A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005012360A3 (en) * | 2003-07-22 | 2005-09-29 | Crucell Holland Bv | Binding molecules against sars-coronavirus and uses thereof |
WO2006095180A2 (en) * | 2005-03-10 | 2006-09-14 | Ultra Biotech Limited | Humananized monoclonal antibodies against sars - associated coronavirus and treatment of patients with sars |
WO2021203034A3 (en) * | 2020-04-03 | 2021-12-02 | Firebreak, Inc. | Alimentary and systemic antiviral therapeutics |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113201068A (zh) * | 2020-02-03 | 2021-08-03 | 深圳市雅臣智能生物工程有限公司 | 基因重组抗2019-nCoV和其它冠状病毒IgY及其小分子抗体以及应用 |
CN111548413B (zh) * | 2020-04-24 | 2021-03-26 | 成都钰康生物科技有限公司 | 一种抗新型冠状病毒的抗体及其制备方法与应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0253737A (ja) * | 1988-08-12 | 1990-02-22 | Takehiko Yamamoto | 多機能特異的抗体の製造方法 |
JP2002165567A (ja) * | 2000-11-30 | 2002-06-11 | Society For Techno-Innovation Of Agriculture Forestry & Fisheries | 有害菌が除去された液状食品の製法 |
US20020107367A1 (en) * | 2000-12-08 | 2002-08-08 | Victor Chiou | Process for isolation and purification of yolk antibodies from avian egg yolk and uses of yolk antibodies obtained thereby |
KR20020068923A (ko) * | 2001-02-23 | 2002-08-28 | 주식회사 중앙가축전염병연구소 | 개 질병 항원을 이용한 특수사료 첨가제의 제조방법 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1290580C (zh) * | 1998-04-01 | 2006-12-20 | 中德联合研究院 | 抗轮状病毒鸡卵黄免疫球蛋白产品 |
CN1206243C (zh) * | 2002-02-08 | 2005-06-15 | 北京市农林科学院畜牧兽医研究所 | 猪传染性胃肠炎病毒卵黄抗体和抗原及其制备 |
-
2003
- 2003-05-13 CN CNB031361013A patent/CN1318449C/zh not_active Expired - Fee Related
- 2003-07-22 AU AU2003255080A patent/AU2003255080A1/en not_active Abandoned
- 2003-07-22 WO PCT/CN2003/000587 patent/WO2004101621A1/zh active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0253737A (ja) * | 1988-08-12 | 1990-02-22 | Takehiko Yamamoto | 多機能特異的抗体の製造方法 |
JP2002165567A (ja) * | 2000-11-30 | 2002-06-11 | Society For Techno-Innovation Of Agriculture Forestry & Fisheries | 有害菌が除去された液状食品の製法 |
US20020107367A1 (en) * | 2000-12-08 | 2002-08-08 | Victor Chiou | Process for isolation and purification of yolk antibodies from avian egg yolk and uses of yolk antibodies obtained thereby |
KR20020068923A (ko) * | 2001-02-23 | 2002-08-28 | 주식회사 중앙가축전염병연구소 | 개 질병 항원을 이용한 특수사료 첨가제의 제조방법 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005012360A3 (en) * | 2003-07-22 | 2005-09-29 | Crucell Holland Bv | Binding molecules against sars-coronavirus and uses thereof |
WO2006095180A2 (en) * | 2005-03-10 | 2006-09-14 | Ultra Biotech Limited | Humananized monoclonal antibodies against sars - associated coronavirus and treatment of patients with sars |
WO2006095180A3 (en) * | 2005-03-10 | 2006-12-21 | Ultra Biotech Ltd | Humananized monoclonal antibodies against sars - associated coronavirus and treatment of patients with sars |
WO2021203034A3 (en) * | 2020-04-03 | 2021-12-02 | Firebreak, Inc. | Alimentary and systemic antiviral therapeutics |
Also Published As
Publication number | Publication date |
---|---|
CN1318449C (zh) | 2007-05-30 |
AU2003255080A1 (en) | 2004-12-03 |
CN1450086A (zh) | 2003-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101328219B (zh) | 纳米脂质体抗人乳头瘤病毒(HPV)及抗妇科炎症病原体特异性复合IgY及其组合制剂 | |
CN103071151B (zh) | 猪支原体肺炎疫苗专用稀释剂及其制备方法 | |
WO2007068154A1 (en) | A method for preparing specific igy against mutant avian influenza virus and the preparation tηereof | |
CN106668832B (zh) | 一种多肽在制备治疗肠道病毒感染药物的应用 | |
CN113087791B (zh) | 广谱抗变异新冠病毒IgY和复合抗体及制备方法和组合制剂 | |
WO2021155639A1 (zh) | 抗SARS-CoV-2和其它冠状病毒IgY及其小分子抗体以及应用 | |
WO2015109578A1 (zh) | 一种猪支原体肺炎减毒活疫苗及其应用 | |
CN101391102A (zh) | 能防治家禽呼吸道疾病的免疫球蛋白复合剂的生产技术 | |
US20230080878A1 (en) | Application of traditional chinese medicine composition in preparation of drugs for treating or preventing coronavirus infection | |
CN108969492A (zh) | 一种猪瘟口服弱毒冻干疫苗及其制备方法 | |
WO2004101621A1 (fr) | Immunoglobuline (ig) y specifique contre le syndrome respiratoire aigu severe (sras), technique de preparation de celle-ci et combinaison de preparations contenant celle-ci | |
US20100196495A1 (en) | Delivery of flu antibodies to surfaces in contact with air | |
CN109055320B (zh) | 一株传染性支气管炎病毒分离株及在疫苗制备中的应用 | |
CN106822885A (zh) | 肺炎链球菌疫苗 | |
CN114377127B (zh) | 一种三联卵黄抗体制剂及其制备方法和应用 | |
JPH07502174A (ja) | 家禽病を発症させる新規バクテリアとそれから誘導されたワクチン | |
TWI359669B (zh) | ||
CN101555281A (zh) | 抗甲型H1N1流感病毒特异性IgY的制备方法及其相关制剂 | |
CN105831391B (zh) | 防治鸡新城疫的中药微生态颗粒剂,饲料及其应用 | |
CN1563088B (zh) | 一种抗流行性感冒特异性复合IgY及其制剂 | |
KR101411995B1 (ko) | 돼지 소모성 질병의 치료 또는 예방을 위한 젖소 초유 항체 조성물 | |
CN108992669B (zh) | 防治呼吸道感染的复合卵黄抗体组合物、雾化吸入溶液剂及制备工艺与应用 | |
CN108703952A (zh) | 一种猪瘟口服弱毒冻干疫苗用冻干保护剂及应用 | |
WO2003104280A1 (fr) | Composition pour lutter contre la pharyngolaryngite contenant de l'igy et son principe actif | |
CN1481900A (zh) | 抗感冒特异性IgY和复合IgY及其新型制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |